NCT06105671 - U-LABA/ICS Effects on Exercise Performance, Formoterol | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 5, 2024

Primary Completion Date

July 4, 2024

Study Completion Date

July 4, 2024

Conditions

Exercise Performance

Interventions

DRUG

Symbicort

Participants are administered 54 μg Formoterol and 1920 μg Budesonide

DRUG

Formoterol

Participants are administered 54 μg Formoterol from an inhaler device

DRUG

Formoterol

Participants are administered 120 μg Formoterol in a capsule, which is taken orally

DRUG

Placebo

Participants are administered placebo

DRUG

Mannitol

Participants are administered 600 mg Bronchitol

Trial Locations (1)

August Krogh Building, Copenhagen

All Listed Sponsors

lead

Morten Hostrup, PhD

OTHER